Pacira BioSciences (PCRX) News Today $16.60 +0.23 (+1.41%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Acquired by Impax Asset Management Group plcImpax Asset Management Group plc grew its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 81.0% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 470,603 shares of the company's stock after purchasing anNovember 16 at 6:36 AM | marketbeat.comPacira announces 104-week safety, efficay data for PCRX-201November 15 at 6:58 AM | markets.businessinsider.comPacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the KneeNovember 14 at 10:05 AM | globenewswire.comLos Angeles Capital Management LLC Has $2.20 Million Stock Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)Los Angeles Capital Management LLC increased its stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 942.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 145,930November 14 at 3:51 AM | marketbeat.comPacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare ConferencesNovember 12, 2024 | finance.yahoo.comBarclays Issues Pessimistic Forecast for Pacira BioSciences (NASDAQ:PCRX) Stock PriceBarclays reduced their target price on Pacira BioSciences from $25.00 to $17.00 and set an "equal weight" rating on the stock in a research report on Tuesday.November 12, 2024 | marketbeat.comRobeco Institutional Asset Management B.V. Invests $1.05 Million in Pacira BioSciences, Inc. (NASDAQ:PCRX)Robeco Institutional Asset Management B.V. bought a new position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 69,944 shares of the company's stock, valued at approximately $1,053,000.November 11, 2024 | marketbeat.comPacira BioSciences, Inc. (NASDAQ:PCRX) Given Average Recommendation of "Hold" by BrokeragesNovember 10, 2024 | americanbankingnews.comPacira BioSciences, Inc. (NASDAQ:PCRX) Q3 2024 Earnings Call TranscriptNovember 8, 2024 | insidermonkey.comPacira BioSciences' (PCRX) Buy Rating Reiterated at Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and set a $22.00 target price on shares of Pacira BioSciences in a research note on Friday.November 8, 2024 | marketbeat.comEvaluating Pacira BioSciences: Insights From 8 Financial AnalystsNovember 8, 2024 | benzinga.comPositive Outlook for Pacira Pharmaceuticals Despite Mixed Q3 2024 Results, Driven by Exparel’s Strong Market Position and Strategic InitiativesNovember 8, 2024 | markets.businessinsider.comRoyal Bank of Canada Issues Positive Forecast for Pacira BioSciences (NASDAQ:PCRX) Stock PriceRoyal Bank of Canada lifted their target price on shares of Pacira BioSciences from $15.00 to $16.00 and gave the company a "sector perform" rating in a research note on Thursday.November 7, 2024 | marketbeat.comPacira Pharmaceuticals Faces Q3 Loss Amid Revenue GrowthNovember 7, 2024 | markets.businessinsider.comPacira BioSciences Inc (PCRX) Q3 2024 Earnings Call Highlights: Strong Financial Position ...November 7, 2024 | finance.yahoo.comPacira Biosciences Inc. (PCRX) Q3 2024 Earnings Call TranscriptNovember 6, 2024 | seekingalpha.comPacira BioSciences Reports Third Quarter 2024 Financial ResultsNovember 6, 2024 | globenewswire.comImpax Asset Management Group plc Has $7.08 Million Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)Impax Asset Management Group plc lifted its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 81.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 470,603 shares of the company'sNovember 6, 2024 | marketbeat.comCenters for Medicare and Medicaid Services (CMS) Establishes Additional Payment for iovera in Outpatient SettingsNovember 5, 2024 | finance.yahoo.comPacira announces CMS established additional payment for iovera in outpatientNovember 5, 2024 | markets.businessinsider.comInsights into Pacira BioSciences's Upcoming EarningsNovember 5, 2024 | benzinga.comPacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Recommendation of "Hold" from AnalystsShares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) have received an average rating of "Hold" from the ten brokerages that are covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and four havNovember 5, 2024 | marketbeat.comPacira BioSciences, Inc. (NASDAQ:PCRX) Shares Sold by Rice Hall James & Associates LLCRice Hall James & Associates LLC trimmed its position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 73.1% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 268,337 shares of the company's stock after selling 730,288 shares durNovember 1, 2024 | marketbeat.comPacira BioSciences (PCRX) Scheduled to Post Quarterly Earnings on WednesdayPacira BioSciences (NASDAQ:PCRX) will be releasing earnings after the market closes on Wednesday, November 6, Zacks reports.October 31, 2024 | marketbeat.comAllspring Global Investments Holdings LLC Increases Stock Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)Allspring Global Investments Holdings LLC grew its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 1,398.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 100,181 shares of the company's stockOctober 31, 2024 | marketbeat.comPacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024October 30, 2024 | globenewswire.comAssenagon Asset Management S.A. Raises Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)Assenagon Asset Management S.A. lifted its stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 314.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 553,114 shares of the company's stock after acquOctober 29, 2024 | marketbeat.comTruist Financial Reaffirms Their Sell Rating on Pacira Pharmaceuticals (PCRX)October 23, 2024 | markets.businessinsider.comPacira BioSciences Names Shawn Cross Chief Financial OfficerOctober 21, 2024 | marketwatch.comAre Options Traders Betting on a Big Move in Pacira BioSciences (PCRX) Stock?October 21, 2024 | finance.yahoo.comPacira BioSciences Appoints Shawn Cross as Chief Financial OfficerOctober 21, 2024 | globenewswire.comZacks Research Equities Analysts Reduce Earnings Estimates for Pacira BioSciences, Inc. (NASDAQ:PCRX)Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) - Zacks Research dropped their Q1 2026 earnings estimates for Pacira BioSciences in a report released on Tuesday, October 15th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $0.73 for theOctober 17, 2024 | marketbeat.comWedge Capital Management L L P NC Raises Stock Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)Wedge Capital Management L L P NC increased its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 131.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 119,447 shares of the company's stock afterOctober 17, 2024 | marketbeat.comPacira BioSciences, Inc. (NASDAQ:PCRX) Given Average Rating of "Hold" by AnalystsPacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) has been assigned a consensus rating of "Hold" from the ten brokerages that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and four have assiOctober 11, 2024 | marketbeat.comPacira BioSciences, Inc. (NASDAQ:PCRX) Shares Sold by Bank of Montreal CanBank of Montreal Can reduced its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 97.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 22,825 shares of the company's stock after selling 982,11October 9, 2024 | marketbeat.comSei Investments Co. Sells 279,140 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)Sei Investments Co. cut its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 85.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 48,683 shares of the company's stock after selling 279,140 shOctober 7, 2024 | marketbeat.comThe three-year loss for Pacira BioSciences (NASDAQ:PCRX) shareholders likely driven by its shrinking earningsOctober 5, 2024 | finance.yahoo.comPacira receives Medicare permanent J-code for ExparelOctober 4, 2024 | msn.comPacira receives Medicare permanent J-code for ExparelOctober 4, 2024 | msn.comPacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025October 3, 2024 | globenewswire.comPacira BioSciences, Inc. (NASDAQ:PCRX) Shares Acquired by Dimensional Fund Advisors LPDimensional Fund Advisors LP increased its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 12.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,828,065 shares of thSeptember 29, 2024 | marketbeat.comExecutive reshuffles: NSC, PCRX and OMI Companies in focusSeptember 28, 2024 | msn.comPacira BioSciences appoints Lauren Riker as interim CFOSeptember 27, 2024 | msn.comPacira BioSciences, Inc. (NASDAQ:PCRX) Shares Bought by Marshall Wace LLPMarshall Wace LLP lifted its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 19.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 971,143 shares of the company's stock after bSeptember 27, 2024 | marketbeat.comPacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the KneeSeptember 26, 2024 | globenewswire.comDoma Perpetual Capital Management LLC Purchases 418,321 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)Doma Perpetual Capital Management LLC boosted its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 71.8% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,000,761 shares of the compSeptember 26, 2024 | marketbeat.comDOMA Perpetual Sends Letter to Board of Directors of Pacira Biosciences to Immediately Accelerate and Increase its Share Buyback Program to Enhance Return to ShareholdersSeptember 25, 2024 | prnewswire.comJefferies Financial Group Boosts Pacira BioSciences (NASDAQ:PCRX) Price Target to $18.00Jefferies Financial Group lifted their price target on Pacira BioSciences from $15.00 to $18.00 and gave the company a "buy" rating in a research report on Tuesday.September 24, 2024 | marketbeat.comPacer Advisors Inc. Grows Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)Pacer Advisors Inc. raised its position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 37.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,162,787 shares of the company's stock after buyinSeptember 22, 2024 | marketbeat.comRenaissance Technologies LLC Acquires 184,000 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)Renaissance Technologies LLC boosted its stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 9.8% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,066,197 shares of the company's stock after buying an additional 184,000September 18, 2024 | marketbeat.com Get Pacira BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address The only candlestick pattern worth a darn (Ad)It’s widely known that 80% of daily market action is driven by Wall Street algorithms… Now, most people think of the algorithms are “bad” When in reality, they are neither good nor bad… They are simply programmed to buy and sell certain stocks over and over again… But here is the thing… They are predictable… They typically buy the same stocks at the same levels over and over again… Follow this link here and enter your email address to sign up… PCRX Media Mentions By Week PCRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PCRX News Sentiment▼0.570.56▲Average Medical News Sentiment PCRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PCRX Articles This Week▼95▲PCRX Articles Average Week Get Pacira BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies OPKO Health News Today ADC Therapeutics News Today Atea Pharmaceuticals News Today Seres Therapeutics News Today Supernus Pharmaceuticals News Today Omeros News Today Nektar Therapeutics News Today Assembly Biosciences News Today Cumberland Pharmaceuticals News Today Agios Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PCRX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacira BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pacira BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
